KYMR
Kymera Therapeutics Inc

838
Mkt Cap
$7.46B
Volume
1.02M
52W High
$103.00
52W Low
$19.45
PE Ratio
-24.49
KYMR Fundamentals
Price
$90.10
Prev Close
$91.35
Open
$89.24
50D MA
$78.97
Beta
1.62
Avg. Volume
861,084.94
EPS (Annual)
-$3.69
P/B
4.64
Rev/Employee
$164,752.10
$5,808.19
Loading...
Loading...
News
all
press releases
Citigroup Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $120.00
Citigroup boosted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $100.00 at Stephens
Stephens raised their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the company an "overweight" rating in a research report on Monday...
MarketBeat·12h ago
News Placeholder
TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR
TD Asset Management Inc lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·14h ago
News Placeholder
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029
Kymera Therapeutics (NASDAQ:KYMR) executives highlighted a sharpened strategic focus on immunology and inflammation at Oppenheimer's 36th Annual Healthcare Conference, emphasizing progress in its...
MarketBeat·2d ago
News Placeholder
Vanguard Group Inc. Cuts Stake in Kymera Therapeutics, Inc. $KYMR
Vanguard Group Inc. cut its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 3.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The...
MarketBeat·3d ago
News Placeholder
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
Zacks·4d ago
News Placeholder
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has earned a consensus recommendation of "Buy" from the twenty-two ratings firms that are currently covering the firm, Marketbeat Ratings...
MarketBeat·4d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate...
MarketBeat·4d ago
News Placeholder
Kymera Therapeutics Q4 Earnings Call Highlights
Kymera Therapeutics (NASDAQ:KYMR) used its fourth-quarter 2025 update call to highlight what management described as a breakout year driven by clinical progress for its oral STAT6 degrader KT-621...
MarketBeat·4d ago
News Placeholder
Analyst Expectations For Kymera Therapeutics's Future
read more...
Benzinga·4d ago
<
1
2
...
>

Latest KYMR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.